Wegovy is approved for weight loss at higher doses, from 0.25 mg to 2.4 mg weekly
In addition, the guidelines were the first time the AAP issued comprehensive recommendations for how pediatricians should approach obesity treatment
Results vary from person to person, but many notice benefits within weeks of treatment
That is the conclusion of a draft report (PDF) from the influential Institute for Clinical and Economic Review (ICER), a US healthcare technology assessment (HTA) organisation, which notes that access to the GLP-1 drugs is already limited by "variable insurance coverage and high out-of-pocket costs." ICER concludes in its document that Novo Nordisk's Wegovy (semaglutide) and Lilly's Zepbound (tirzepatide) are clearly a step forward in helping people lose weight and improve their metabolic health, after saying in an earlier report (PDF) that their prices needed to come down
So, how can you tell if your body is missing something important
Novo said its competitor compared the highest approved doses of its medicines for obesity and type-2 diabetes with lower doses of Novo Nordisk's, while omitting newer, higher-dose options
